Article Figures & Data
Figures
- Fig 1.
Line graph showing change in size over time relative to baseline CT. A, Fifty percent of nodes showed initial growth followed by decreased size. One node (marked with an asterisk at last time point) demonstrated a continued increase in size, but could not be followed after 184 days. B, Forty-two percent of nodes showed a downward trend in size. The final size was smaller than baseline in all nodes except for the one indicated in A.
- Fig 2.
A, Coronal contrast-enhanced CT shows a round, well-circumscribed necrotic lesion (black arrow) at the inferior aspect of the right parotid gland. B, The lesion has increased in size and developed infiltrative margins (white arrow) 72 days after injection. Follow-up at 111 days (C) and 184 days (D) after injection demonstrates further growth and marked increase in central necrosis. E, The lesion shows decreased size after 337 days.
- Fig 3.
A, Axial contrast-enhanced CT shows a small nodule in the deep right breast/axillary region (white arrow). The lesion shows slight central hypoattenuation and increased size at 34 days after injection (white arrow, B) with the development of frank central necrosis after 72 days (black arrow, C). There is a mild further increase in size at 104 days (D), followed by decreased size at 125 days (E) and near complete resolution at 174 days (F).
Tables
Clinical features, disease stage, final nodal size (relative to baseline CT), and patient outcome
Patient No. Lesion No. Age, yr Sex Stage BRAF Status Location Final Lesion Size Patient Outcome 1 1 63 F T3bN3M1a Negative Left supraclavicular Decreased Remission. 2 2 66 M TxNxM1c Wild type Right supraclavicular Decreased T-VEC discontinued after disease progression in ribs. Placed on nivolumab with partial response. 3 Right supraclavicular Decreased 3 4 40 M pT1bN3M1c Positive Right preauricular Decreased IL-2 followed by BRAF and MEK inhibitors after ipilimumab/T-VEC treatment. Deceased. 5 Right submandibular Decreased 4 6 44 M T3bN3M1b Positive Right axillary Decreased BRAF and MEK inhibitors after ipilimumab/T-VEC treatment, followed by disease progression. Deceased. 7 Right axillary Decreased 5 8 58 F T3bN2M1a Wild type Left upper back Decreased Complete response for 21 months, followed by axillary recurrence. Placed on nivolumab. 9 Left breast Decreased 6 10 32 M T4bN3M1a Negative Left retroauricular Decreased Partial response for 6 months. Placed on nivolumab. 7 11 63 M T3aN3M1c Negative Right chest wall Increased Rapid deterioration after brain metastases. Deceased. 12 Right axilla Decreased Note:—IL-2 indicates interleukin 2.
Jump to section
Related Articles
Cited By...
- No citing articles found.